D. Martin

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition

M. Hegen, J. Telliez, M. Dowty, 2019, Pharmacology research & perspectives.

Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States

N. Gatto, D. Esposito, K. Mues, 2022, Vaccine.

Contribution of a European‐Prevalent Variant near CD83 and an East Asian–Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome‐Wide Association Study Meta‐Analyses

N. Bing, Y. Kochi, Baohong Zhang, 2021, Arthritis & rheumatology.

After 25 years of drug development, do we know JAK?

H. Schulze-Koops, M. Mortezavi, D. Martin, 2022, RMD Open.

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

S. Paciga, C. Hyde, J. Weitz, 2022, RMD Open.

Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US

C. Boileau, T. Ducruet, A. Rosen, 2023, medRxiv.

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

V. Sikirica, E. Peeva, P. Mease, 2023, Arthritis & rheumatology.